Preliminary Clinical Study on the Effect of L-ornithine on the Efficacy of Ustekinumab in Patients With Crohn's Disease
A Single Center, Randomized Controlled Clinical Study on the Effect of L-ornithine on the Efficacy of Ustekinumab in Patients With Crohn's Disease
The Third Xiangya Hospital of Central South University
50 participants
Apr 1, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to evaluate the effect of supplementing L-ornithine compared to the control group on the efficacy of Ustekinumab in patients with Crohn's disease, and to summarize the role of supplementing L-ornithine in the treatment of CD patients. Participants will be randomized into two groups: the L-ornithine supplementation group and the control group. The patients in the L-ornithine supplementation group received oral ornithine capsules for 8 weeks. The control group did not receive additional intervention. Follow up once a week, and after the study, patients will come to the hospital to finish the evaluation indicators.
Eligibility
Inclusion Criteria4
- Age ≥ 18 years old, ≤ 75 years old;
- Patients clinically diagnosed with Crohn's disease shall refer to the Chinese Guidelines for the Diagnosis and Treatment of Crohn's Disease (Guangzhou, 2023) for diagnostic criteria;
- Patients receiving treatment with Ustekinumab;
- Agree to participate in this study and sign an informed consent form.
Exclusion Criteria10
- Participants who meet any of the following criteria are not eligible for inclusion in this study.
- Patients with ALT or AST exceeding the normal upper limit by more than twice, and TBIL exceeding the normal upper limit by more than twice;
- Patients with creatinine clearance rate less than 60ml/min;
- Patients with severe active infections in the intestines or other areas that require the use of antibiotics or antiviral drugs;
- Patients with intestinal tuberculosis, other chronic intestinal infectious diseases, and intestinal malignant tumors;
- Pregnant and lactating women;
- The fasting blood glucose of patients with diabetes or screening period exceeds 7.0mmol/L or glycosylated hemoglobin exceeds 6.5%;
- Merge patients with severe mental illness, drug use, alcohol abuse, etc. who are unable to cooperate with the study;
- Have participated in any other clinical research within the first month prior to enrollment;
- The researcher determined that any other disease or condition is not suitable for patients participating in this study.
Interventions
L-ornithine is an amino acid that helps the liver clear toxic ammonia and plays an important role in liver protection and treatment of hepatic encephalopathy. Now Foods L-ornithine capsules are an ornithine supplement containing 500mg of L-ornithine per capsule. Patients in the L-ornithine supplementation group take ornithine capsules orally twice a day, three capsules each time, for 8 weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06455267